



Diabetes Collaborative Registry

Unless indicated, the Diabetes Collaborative Registry® measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer programs or other forms of accountability. For additional information related to the metrics, refer to this website: <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents>

PROGRAM MEASURES & METRICS

Measure ID	Measure Description	Developer	NQF #
Diabetes Collaborative Registry-1	Diabetes: Hemoglobin A1c Poor Control: Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c>9.0% during the measurement period (12 months from date of encounter)	NCQA	0059
Diabetes Collaborative Registry-2	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%): Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes or a current or prior LVEF < 40% who were prescribed an ACE inhibitor or ARB therapy	ACCF	N/A
Diabetes Collaborative Registry-3	Diabetes: Medical Attention for Nephropathy: Percentage of patients 18-75 years of age with diabetes who had nephropathy screening test or evidence of nephropathy during the measurement period	NCQA	0062
Diabetes Collaborative Registry-4	Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	ACCF	N/A
Diabetes Collaborative Registry-5	Dietary Intake Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to eat a healthy diet	AHA/ACCF	N/A
Diabetes Collaborative Registry-6	Physical Activity Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to engage in regular physical activity	AHA/ACCF	N/A
Diabetes Collaborative Registry-7	Peripheral Artery Disease (PAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Risk: Percentage of patients 18-75 years of age with PAD who were offered moderate-to-high intensity statin	AHA/ACCF	N/A
Diabetes Collaborative Registry-8	Diabetes Eye Exam: Percentage of patients aged 18 and older with diabetes who received an eye exam	NCQA	0055



Diabetes Collaborative Registry

Diabetes Collaborative Registry-9	Diabetes Foot Exam: Percentage of patients aged 18 and older with diabetes who received a foot exam	NCQA	0056
Diabetes Collaborative Registry-11	Antiplatelet Therapy: Percentage of patients aged 18 and older who received antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or vascular death in patients with a history of symptomatic PAD	ACCF/AHA/ ACR/SCAI/ SIR/SVM/ SVN/SVS	N/A
Diabetes Collaborative Registry-13	Coronary Artery Disease (CAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Percentage of patients ages 18-75 with CAD who were offered moderate-to-high intensity statin	ACC/AHA/ AMA-PCPI	N/A
Diabetes Collaborative Registry-15	Hypertension: Blood Pressure Treatment and Control for High Risk Patients: Proportion of adults, ≥ 18 years of age, with both hypertension and diabetes who were prescribed antihypertensive medication or who had adequately controlled blood pressure	ACCF	N/A

Diabetes Collaborative Registry (DCR) participants include clinicians in primary care, endocrinology and cardiology outpatient settings. Eligible providers must be able to report at least 6 of the metrics listed above to participate in DCR.

Veradigm® is an Allscripts company.

©2020 Veradigm® Allscripts Healthcare LLC, and/or its affiliates. All rights reserved. Cited marks are the property of Allscripts Healthcare, LLC and or its affiliates.

All other product or company names are the property of their respective holders, all rights reserved.